このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Acupuncture for Sleep Fragmentation in Older Adults: A Single-Arm Pilot Study

2026年9月20日 更新者：Geng-Hao Liu、Chang Gung Memorial Hospital

Translational Research on Acupuncture Modulation of Sleep Fragmentation and Glymphatic Function in Aging: A Single-Arm Pilot Study

This single-group pilot study will enroll 20 adults aged 60 years or older with persistent poor sleep. All participants will receive a standardized 6-week acupuncture program. The study will assess feasibility and preliminary changes in actigraphy-derived sleep fragmentation, self-reported sleep, brain DTI-ALPS imaging, internal jugular venous ultrasonography, and CERAD-NB word-list memory performance.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

After written informed consent, participants will complete cognitive and mood screening. Baseline assessments include PSQI, ISI, ESS, CERAD-NB word-list memory testing, one night of home polysomnography, 7 days of actigraphy, brain MRI for the DTI-ALPS index, and internal jugular venous ultrasonography. Participants will then receive acupuncture twice weekly for 6 weeks, for 12 sessions, with each session lasting approximately 20 to 30 minutes. ISI will also be assessed at Weeks 2 and 4. At Week 6, baseline assessments will be repeated except for home polysomnography. PSQI, ISI, and ESS will be collected again approximately 3 months after treatment as an optional follow-up. Missing data from this optional follow-up alone will not exclude a participant from the per-protocol population. Exploratory analyses will examine whether actigraphy-derived physical activity and light exposure are associated with, or modify, changes in the registered sleep, imaging, and cognitive outcomes.

研究の種類

介入

入学 (推定)

20

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • 台湾
    • Taoyuan
      • Taoyuan、Taoyuan、台湾、333
        • Linkou Chang Gung Memorial Hospital
        • コンタクト：
      • Taoyuan、Taoyuan、台湾、333
        • Taoyuan Chang Gung Memorial Hospital
        • コンタクト：

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

60年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age 60 years or older.
  2. Subjective poor sleep for at least 3 months.
  3. Pittsburgh Sleep Quality Index (PSQI) total score greater than 5.
  4. Willing and able to complete study assessments and the 6-week intervention.
  5. Mini-Mental State Examination (MMSE) score of 24 or higher.
  6. Provides written informed consent.

Exclusion Criteria:

  1. Diagnosed dementia, Parkinson disease, or another progressive neurodegenerative disorder.
  2. Stroke or severe head injury within the prior year.
  3. Unstable major psychiatric illness.
  4. AD8 score of 2 or higher or Geriatric Depression Scale (GDS) score of 5 or higher.
  5. Severe sensory or comprehension problems that prevent study participation.
  6. Night-shift work or frequent recent transmeridian travel.
  7. Current CPAP or BiPAP use, or severe obstructive sleep apnea requiring immediate treatment, such as an apnea-hypopnea index greater than 30 with oxygen desaturation.
  8. Use of 3 or more hypnotic medications with inability to maintain a stable dose.
  9. Contraindication to magnetic resonance imaging.
  10. Major neck surgery, neck radiation, or vascular anomaly that interferes with jugular ultrasonography.
  11. Severe unstable systemic disease.
  12. Severe coagulopathy or anticoagulation that makes acupuncture unsuitable.
  13. Infection or wound at an acupuncture site.
  14. Severe gait instability or inability to attend scheduled visits.
  15. Any other condition that the investigator considers unsuitable for participation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：なし
  • 介入モデル：単一グループの割り当て
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
実験的：Acupuncture

Participants receive a 6-week standardized acupuncture program.
手順：Acupuncture

Participants will receive acupuncture at Baihui (GV20), Anmian (EX-HN22), Zusanli (ST36), and Taixi (KI3) twice weekly for 6 weeks, for a total of 12 sessions. Needles will be retained for approximately 20 to 30 minutes per session. No comparator arm is used in this pilot.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in 7-day mean wake after sleep onset from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. Wake after sleep onset (WASO) is the total minutes scored awake between sleep onset and final awakening for each valid night. Sleep is measured with Actiwatch 2 (Philips Respironics) worn on the nondominant wrist, recorded in 60-second epochs, and scored with Philips Actiware version 6.0.9 using sleep diaries. Each timepoint is the mean across all valid nights in the 7-day assessment window. A timepoint is valid if it includes at least 5 valid nights, including at least 1 weekend night; otherwise it is treated as missing. Unit: minutes.
Baseline and Week 6

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in 7-day mean sleep efficiency from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. Sleep efficiency is the percentage of time in bed scored as sleep for each valid night. Sleep is measured with Actiwatch 2 (Philips Respironics) worn on the nondominant wrist, recorded in 60-second epochs, and scored with Philips Actiware version 6.0.9 using sleep diaries. Each timepoint is the mean across all valid nights in the 7-day assessment window. A timepoint is valid if it includes at least 5 valid nights, including at least 1 weekend night; otherwise it is treated as missing. Unit: percentage points.
Baseline and Week 6
Change in Pittsburgh Sleep Quality Index total score over time
時間枠：Baseline, Week 6, and approximately 3 months after treatment

The Pittsburgh Sleep Quality Index total score ranges from 0 to 21; higher scores indicate poorer sleep quality. Change at Week 6 and at the optional approximately 3-month post-treatment follow-up equals the respective follow-up score minus baseline.
Baseline, Week 6, and approximately 3 months after treatment
Change in 7-day mean number of awakenings from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. Actiware-derived awakenings are counted for each valid night. Sleep is measured with Actiwatch 2 (Philips Respironics) worn on the nondominant wrist, recorded in 60-second epochs, and scored with Philips Actiware version 6.0.9 using sleep diaries. Each timepoint is the mean across all valid nights in the 7-day assessment window. A timepoint is valid if it includes at least 5 valid nights, including at least 1 weekend night; otherwise it is treated as missing. Unit: awakenings per night.
Baseline and Week 6
Change in 7-day mean sleep fragmentation index from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. For each valid night, the Actiware 6.0.9 sleep fragmentation index is the sum of (1) the percentage of epochs classified as mobile during the sleep interval and (2) the percentage of all immobile bouts lasting no more than 1 minute. Higher values indicate greater sleep fragmentation. Actiwatch 2 is worn on the nondominant wrist and recorded in 60-second epochs. Each timepoint is the mean across valid nights in the 7-day window. A timepoint requires at least 5 valid nights, including at least 1 weekend night; otherwise it is missing. Unit: percentage points.
Baseline and Week 6
Change in Insomnia Severity Index total score over time
時間枠：Baseline, Weeks 2, 4, and 6, and approximately 3 months after treatment

The Insomnia Severity Index total score ranges from 0 to 28; higher scores indicate greater insomnia severity. Change at Weeks 2, 4, and 6 and at the optional approximately 3-month post-treatment follow-up equals the respective follow-up score minus baseline.
Baseline, Weeks 2, 4, and 6, and approximately 3 months after treatment
Change in Epworth Sleepiness Scale total score over time
時間枠：Baseline, Week 6, and approximately 3 months after treatment

The Epworth Sleepiness Scale total score ranges from 0 to 24; higher scores indicate greater daytime sleepiness. Change at Week 6 and at the optional approximately 3-month post-treatment follow-up equals the respective follow-up score minus baseline.
Baseline, Week 6, and approximately 3 months after treatment
Change in diffusion tensor imaging along the perivascular space index from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 value minus the baseline value for the diffusion tensor imaging along the perivascular space (DTI-ALPS) index. Unit: unitless (dimensionless index).
Baseline and Week 6
Change in side-specific internal jugular vein time-averaged mean blood-flow velocity from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 value minus baseline for time-averaged mean velocity measured by pulsed-wave Doppler ultrasonography with the participant supine and the head in a neutral position. The left and right internal jugular veins are measured and analyzed separately; values are not combined by a simple bilateral average. Repeated measurements for each side are averaged. Unit: centimeters per second (cm/s).
Baseline and Week 6
Change in side-specific internal jugular vein cross-sectional area from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 value minus baseline for cross-sectional area measured by transverse B-mode ultrasonography with the participant supine and the head in a neutral position. The left and right internal jugular veins are measured and analyzed separately; values are not combined by a simple bilateral average. Repeated measurements for each side are averaged. Minimal transducer pressure is used to avoid vein compression. Unit: square centimeters (cm²).
Baseline and Week 6

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in CERAD-NB word-list memory composite score from baseline to Week 6
時間枠：Baseline and Week 6

Change equals the Week 6 score minus baseline. The composite is the sum of word-list learning across 3 trials (0-30), delayed recall (0-10), and recognition discriminability (0-10), for a total range of 0-50; higher scores indicate better memory performance. Recognition discriminability is calculated as correct "Yes" responses plus correct "No" responses minus 10; values below 0 are scored as 0. Remote memory is not included in this composite.
Baseline and Week 6
Proportion of participants completing at least 10 of 12 acupuncture sessions
時間枠：Through Week 6

Number of enrolled participants who complete at least 10 of the 12 planned acupuncture sessions divided by the total number enrolled, multiplied by 100. This threshold corresponds to at least 80% treatment adherence. Unit: percentage of participants.
Through Week 6
Proportion of participants completing the Week 6 primary outcome assessment
時間枠：Week 6

Number of enrolled participants who complete the Week 6 assessment of the primary outcome, 7-day mean wake after sleep onset, divided by the total number enrolled, multiplied by 100. Unit: percentage of participants.
Week 6
Proportion of participants with valid actigraphy data at both baseline and Week 6
時間枠：Baseline and Week 6

Number of enrolled participants with valid actigraphy timepoints at both baseline and Week 6 divided by the total number enrolled, multiplied by 100. Each timepoint requires at least 5 valid nights, including at least 1 weekend night. Unit: percentage of participants.
Baseline and Week 6

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Chang Gung Memorial Hospital

協力者

National Science and Technology Council, Taiwan

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2027年7月31日

研究の完了 (推定)

2027年10月31日

試験登録日

最初に提出

2026年9月20日

QC基準を満たした最初の提出物

2026年9月20日

最初の投稿 (実際)

2026年9月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月20日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 202502000A3-PILOT
  • NSTC 115-2320-B-182-022-MY3 (その他の助成金/資金番号：National Science and Technology Council, Taiwan)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する